Study background and rationale
Hemodynamically significant patent ductus arteriosus (hsPDA) is a common cause of morbidity and mortality among preterm infants (1, 2) . Treatment options for the closure of hsPDA include pharmacological therapy and surgical ligation. Indomethacin and Ibuprofen, both block the conversion of arachidonic acid to prostaglandins, are the two most commonly used drugs for closure of PDA. (3, 4) . The reported treatment success with ibuprofen for the management of hsPDA is between 70%-85% (5-8). Several adverse effects have been reported with such medications, including peripheral vasoconstriction, gastrointestinal bleeding and perforation, decreased platelet aggregation, hyperbilirubinemia, and renal failure (9, 10) . Paracetamol (also known as acetaminophen), unlike Ibuprofen, acts on prostaglandin synthase at the peroxidase region of the enzyme (11) . Paracetamol inhibition is facilitated by a decreased local concentration of hydroperoxides (12) . The role of paracetamol as an alternative treatment for the closure of hsPDA has gained attention in recent years because of the potential side-effects of cyclooxygenase inhibitors (13) (14) (15) . Five case series consisting of 39 patients had reported a PDA closure rate of 84-100% in neonates where treatment with indomethacin or Ibuprofen failed or were contraindicated (13, 14, 16, 17) . One trial with 80 subjects concluded Oral Paracetamol is not superior to Oral Ibuprofen (18) whereas another trial with 160 subjects reported Oral
Paracetamol not inferior to Oral Ibuprofen in closure of PDA (19) . Considering the equivocal reports and the promise offered by paracetamol as a safer alternative, this randomized, active controlled, non-inferiority trial was planned. A trans-ductal diameter of ≥ 1.5 mm plus one of the following:
• Evidence of left atrial enlargement (LA: Ao root diameter ratio ≥1.4)
• Ductal velocity < 2 meters/sec
• Antegrade main pulmonary artery diastolic flow >20 cm/sec
• E: A ratio >1
• Isovolemic relaxation time (IVRT) ≤45 milliseconds 
Consent:
One of the parents would be approached for consent to allow their newborn infant to participate in this clinical trial. The parents will be provided a detailed parent information sheet and will also receive a verbal explanation about the study. Neonates will be enrolled only after obtaining written informed consent from one of the parents. Parents would be allowed to withdraw their neonate from the study at any stage.
Intervention and comparison groups
Intervention: Paracetamol oral suspension (Calpol, Glaxo Smithkline Asia Pvt Ltd) would be administered through an oro-gastric tube in a dose of 15 mg/kg/dose at 6 hourly intervals for three consecutive days. The drug would be filled in 5 ml plastic syringes and would be gently pushed through the oro-gastric tube followed by a flush of 1 ml of sterile water for injection Active control: Ibuprofen oral suspension (Ibugesic, Cipla India Ltd.) would be administered through oro-gastric tubes in a dose of 10 mg/kg/dose followed by 5 mg/kg/dose after 24 and 48
hours from the first dose. A similar drug administration technique would be followed as stated above
Allocation process
Web based random allocation would be done within each of the three strata (<28 weeks, 28-29 and 30-31 weeks) (http://www.randomization.com). A block randomization would be done with blocks of variable sizes within each stratum. Separate personnel who are not involved in any aspect of the trial would do the random allocation.
Allocation concealment and blinding
The drugs would be prepared and dispensed by the clinical pharmacy department of the Institute.
The drugs would be dispensed in 5 ml volumes in separate vials as per the group of allocations.
Allocation concealment would be ensured by serially numbering the vials with a randomly generated code number corresponding to the sequence of allocation. The drugs would be prepared to have a similar color, flavor, and viscosity to prevent identification of the study drug 
Technique of transthoracic echocardiography
The Echocardiographic assessments will be done using a SonoSite MicroMaxx Portable
Ultrasound Machine (Fujifilm Sonosite Inc. Bothell, WA 98021, USA); Philips CX-50 machine (Philips Healthcare, Massachusetts, USA) in site 2 and Esaote MyLab 5 (Esaote Inc.
Genova, Italy) in site 3. A cardiac probe of 8-12 MHz frequency will be utilized for the study. Before the procedure, the probe head will be cleaned and cold-disinfected with 2% glutaraldehyde solution. Three standard views would be optimized for visualization of the ductus arteriosus -subxiphoid, high parasternal (ductal) and aortic arch (suprasternal) views.
Presence of ductus in a 2-D would always be crosschecked using a color Doppler superimposition. Transductal diameter would be measured preferably in a 2-D in a high parasternal cut. To maintain uniformity, the diameter measurement will be done at the narrowest point by 2-D imaging, which is usually at the pulmonary end of the ductus arteriosus, where it constricts first. Color Doppler mapping would be used to visualize the direction of shunt blood flow. Ductal velocity would be assessed using pulsed wave Doppler The observed rate of PDA closure by oral Ibuprofen was 85% (20). Assuming an equal rate of closure for oral paracetamol with a non-inferiority margin of 15%, one sided alpha error of 5%
and power of 90%, 196 neonates would be required in this trial. The primary outcome (binary) of rate of closure of PDA will be compared between the study groups by calculating the relative risk and risk difference and would be expressed as 95% C.I. Baseline variables would be compared between the study groups using Chi-square test for categorical variables and student 't' test or an appropriate nonparametric test for numerical variables. Time to closure of PDA would be compared by a Kaplan-Meier curve and significance will be tested by log rank test.
Both intention to treat and per protocol analysis will be done to assess the effect of contamination and protocol violations on the primary outcome. Apart from hypothesis testing for non-inferiority using the non-inferiority margin assumed, the 95% CI of the probability of closure of PDA would be marked to establish or reject non-inferiority of Paracetamol in There were also no significant differences between the paracetamol and the ibuprofen groups in the secondary outcomes except for 'duration for need of supplemental oxygen' and for hyperbilirubinemia, both in favor of paracetamol. However, both the studies included were graded down by the review group as low in quality using the GRADE process. Another recent systematic review of sixteen studies (2 randomized controlled trials and 14 uncontrolled studies)
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Objectives

Primary objective
To study the efficacy of Oral Paracetamol for closure of HS-PDA in comparison to Oral
Ibuprofen in preterm neonates of <32 weeks' gestation with evidence of HS-PDA
Secondary objectives
To compare the following between Oral Paracetamol and Oral Ibuprofen groups:
• Time to closure of PDA
• Proportion of neonates where PDA closed following a single course
• Proportion of neonates who required surgical ligation for closure of PDA
• All-cause mortality before discharge from hospital
• Proportion of neonates where the PDA reopened
• Incidence of echocardiography proven pulmonary artery hypertension 
• Duration of mechanical ventilation (in days)
• Duration of any respiratory support (in days)
• Duration of need for supplemental oxygen (in days)
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Consent:
Intervention and comparison groups
Allocation process
Allocation concealment and blinding
Allocation concealment would be ensured by serially numbering the vials with a randomly generated code number corresponding to the sequence of allocation. The drugs would be prepared to have a similar color, flavor, and viscosity to prevent identification of the study drug and would be dispensed on opaque plastic vials. The blinding process would be tested by administering the dispensed drugs to adult volunteers to assess whether they can differentiate the 
Technique of transthoracic echocardiography
Genova, Italy) in site 3. A cardiac probe of 8-12 MHz frequency will be utilized for the study.
Before the procedure, the probe head will be cleaned and cold-disinfected with 2% glutaraldehyde solution. Three standard views would be optimized for visualization of the ductus arteriosus -subxiphoid, high parasternal (ductal) and aortic arch (suprasternal) views. The observed rate of PDA closure by oral Ibuprofen was 85% (23). Assuming an equal rate of closure for oral paracetamol with a non-inferiority margin of 15%, one sided alpha error of 5%
Both intention to treat and per protocol analysis will be done to assess the effect of contamination and protocol violations on the primary outcome. Apart from hypothesis testing for non-inferiority using the non-inferiority margin assumed, the 95% CI of the probability of closure of PDA would be marked to establish or reject non-inferiority of Paracetamol in comparison to oral ibuprofen. A 'p' value of 0.05 would be considered significant. IBM-SPSS v.20 will be used for data entry and statistical analysis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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